

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FIL	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/657,508	0	9/08/2003	Eliezer Zomer	9324	
32361	7590	04/14/2006		EXAMINER	
GREENBER		,	KHARE, DEVESH		
MET LIFE BUILDING 200 PARK AVENUE				ART UNIT	PAPER NUMBER
NEW YORK,	NY 10	166	1623		

DATE MAILED: 04/14/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	10/657,508	ZOMER ET AL.	
Office Action Summary	Examiner	Art Unit	
	Devesh Khare	1623	
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet v	ith the correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING Description of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period. Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUN 136(a). In no event, however, may a will apply and will expire SIX (6) MO te, cause the application to become A	ICATION. reply be timely filed NTHS from the mailing date of this communic BANDONED (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on			
,	s action is non-final.		
3) Since this application is in condition for allowa		ters, prosecution as to the merit	ts is
closed in accordance with the practice under	·		
Disposition of Claims			
4)⊠ Claim(s) 1-25 is/are pending in the application	n.		
4a) Of the above claim(s) is/are withdra	·		
5) Claim(s) is/are allowed.			
6)☐ Claim(s) is/are rejected.			
7) Claim(s) is/are objected to.			
8)⊠ Claim(s) <u>1-25</u> are subject to restriction and/or	election requirement.		
Application Papers			
9) The specification is objected to by the Examin	er.		
10)☐ The drawing(s) filed on is/are: a)☐ ac	cepted or b) objected to	by the Examiner.	
Applicant may not request that any objection to the	e drawing(s) be held in abeya	nce. See 37 CFR 1.85(a).	
Replacement drawing sheet(s) including the correct	·		
11)☐ The oath or declaration is objected to by the E	xaminer. Note the attache	d Office Action or form PTO-152	2.
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:	n priority under 35 U.S.C.	§ 119(a)-(d) or (f).	
1.☐ Certified copies of the priority documen	its have been received.		
2. Certified copies of the priority documen		Application No	
3. Copies of the certified copies of the price	ority documents have been	received in this National Stage	!
application from the International Burea	au (PCT Rule 17.2(a)).		
* See the attached detailed Office action for a lis	t of the certified copies no	received.	
Attachment(s)			
1) Motice of References Cited (PTO-892) Discription Notice of Draftsperson's Patent Drawing Review (PTO-948)		Summary (PTO-413) (s)/Mail Date	
Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date		Informal Patent Application (PTO-152)	

Election/Restrictions

Restriction is required under 35 U.S.C. 121:

- I. Claims 1-12 drawn to a composition one or more polysaccharide and one or more therapeutic agent, classified in classes 514, 424 and 536, subclass various.
- II. Claims 13-25, drawn to a method for treating cancer, comprising administering to a subject in need thereof by the composition of Group I, wherein the polysaccharide is galactomannan of claim 5, classified in classes 514, subclass various.

The inventions are distinct, each from the other because of the following reasons:

Groups I to II are related as product and process of using. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the claims are drawn to a method for treating cancer, comprising administering to a subject in need thereof by the composition of Group I, wherein the polysaccharide is galactomannan of claim 5, indicating that the cancer can be treated by a different product such as a pharmaceutical compound wherein a therapeutic agent is covalently linked to a spacer which is covalently linked to a

Application/Control Number: 10/657,508

Art Unit: 1623

galactose moiety thru an ether bond (see abstract: Klyosov et al. U.S. Patent

6,642,205).

Although the inventions are classified in the same class and sub-class, searching the two groups of inventions constitutes a burdensome search, as a thorough search comprises a search or foreign patents and non-patent literature as well as the appropriate U.S. patent classifications. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their divergent subject matter, restriction for examination purposes as indicated is proper. It is noted that examination of the three independent and distinct inventions would indeed impose an undue burden upon the examiner in charge of this application.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143). If applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims, which depend from or otherwise include all the limitations of the allowable product claim will be rejoined. (MPEP § 821.04)

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Application/Control Number: 10/657,508

Art Unit: 1623

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

A telephone call was made to Janine Susan on 10/31/05 and Jonathan Guest on 4/06/06, to request an oral election to the above restriction requirement, but did not result in an election being made.

Any inquiry concerning this communication or earlier communications from the

Examiner should be directed to Devesh Khare whose telephone number is (571)272-0653. The examiner can normally be reached on Monday to Friday from 8:00 to 4:30.

Application/Control Number: 10/657,508 Page 5

Art Unit: 1623

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anna Jiang, Supervisory Patent Examiner, Art Unit 1623 can be reached at (571)272-0627. The official fax phone numbers for the organization where this application or proceeding is assigned is (703) 308-4556 or 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Devesh Khare, Ph.D.,J.D.

Art Unit 1623 April 6, 2006